Lobby organisation
Novartis International AG
Company · Health & pharma · HQ: Switzerland · Transparency Register entry
As of 7 November 2026, Novartis International AG appears in 107 declared MEP meetings (72 different MEPs), most often with European People's Party.
In their own words
“Bringing breakthroughs to more patients At Novartis, we don’t just discover life-changing medicines, we're part of a broader effort to help ensure medicines reach the people who need them most, wherever they live, because the true value of innovation lies in its ability to improve lives.”
Read the rest of the statementShow less of the statement
“Ensuring people everywhere can benefit from the latest medical breakthroughs is a shared global responsibility – one we care deeply about and work hard to uphold through our science, value and access initiatives, and government and community partnerships. Yet, this shared responsibility has grown out of balance, with a disproportionate burden placed on certain countries and even patients. Our mission is simple: push the boundaries of science and ensure every breakthrough reaches those who need it fairly, affordably, and without delay because every patient deserves a future shaped by innovation. https://www.novartis.com/news/bringing-breakthroughs-more-patients […]”
Stated goals from the organisation's own Transparency Register filing - the text on file breaks off mid-sentence where marked […].
Who they meet, and when
Which groups they meet
Share of this organisation's 107 declared meetings, by the meeting MEP's political group.
Meetings by year
Declared meetings per calendar year, 2020–2026. Bar length is relative to its busiest year (36 in 2026). Hatched: 2026 is a part-year - the record runs to 6 Nov 2026.
Group is each MEP's current political group, not necessarily the one they sat with at the time. Shares are rounded to whole percent.
The MEPs they meet most
The 15 most recent declared meetings
| Date | MEP | Subject |
|---|---|---|
| 27 Aug 2026 | Lukas Mandl | Biotech Act |
| 8 Jul 2026 | Lukas Mandl | Biotech Act I |
| 3 Jul 2026 | Billy Kelleher | EU-US Relations / Clinical Trials / Bio Tech Act |
| 11 Jun 2026 | João Cotrim de Figueiredo | Competitividade europeia, investigação e inovação, reforço do Mercado Único e a agenda de segurança económica |
| 10 Jun 2026 | Aurelijus Veryga | Biotechnology Innovation, Health Policy and European Competitiveness |
| 10 Jun 2026 | Zala Černilec Tomašič | Annual meeting with Slovenian pharmaceutical industry |
| 10 Jun 2026 | Marta Temido | Apresentação do contributo e as principais iniciativas da Novartis em Portugal |
| 10 Jun 2026 | Margarita de la Pisa Carrión | BIOTECH ACT |
| 10 Jun 2026 | Cynthia Ní Mhurchú | IMCO opinion on MDR/IVDR file |
| 10 Jun 2026 | Elżbieta Katarzyna Łukacijewska | Biotech Act |
| 10 Jun 2026 | Sérgio Humberto | Biotech |
| 10 Jun 2026 | Sérgio Gonçalves | Health |
| 10 Jun 2026 | Paulo Cunha | Biotech Act |
| 9 Jun 2026 | Auke Zijlstra | Biotech |
| 9 Jun 2026 | Alexandr Vondra | Urban Waste Water Treatment Directive |
Meeting an MEP is a normal part of democratic life; the record is shown so anyone can see it.